In the latest trading session, 0.42 million Lyra Therapeutics Inc (NASDAQ:LYRA) shares changed hands as the company’s beta touched -0.16. With the company’s most recent per share price at $0.21 changing hands around $0.0 or 1.85% at last look, the market valuation stands at $13.71M. LYRA’s current price is a discount, trading about -3133.33% off its 52-week high of $6.79. The share price had its 52-week low at $0.16, which suggests the last value was 23.81% up since then.
Analysts gave the Lyra Therapeutics Inc (LYRA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended LYRA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Lyra Therapeutics Inc’s EPS for the current quarter is expected to be -0.13.
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Instantly LYRA is in green as seen in intraday trades today. With action 0.62%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 1.50%, with the 5-day performance at 0.62% in the green. However, in the 30-day time frame, Lyra Therapeutics Inc (NASDAQ:LYRA) is 12.45% up.
The consensus price target for the stock as assigned by Wall Street analysts is 0.5, meaning bulls need an upside of 58.0% from its recent market value. According to analyst projections, LYRA’s forecast low is 0.5 with 0.5 as the target high. To hit the forecast high, the stock’s price needs a -138.1% plunge from its current level, while the stock would need to soar -138.1% for it to hit the projected low.
Lyra Therapeutics Inc (LYRA) estimates and forecasts
Year-over-year growth is forecast to reach -2.21% down from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 206k. The company’s revenue for the corresponding quarters a year ago was 146k and 532k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 41.10%. The estimates for the next quarter sales put growth at -100.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -21.63%. The 2025 estimates are for Lyra Therapeutics Inc earnings to decrease by -5.36%, but the outlook for the next 5-year period is at 14.56% per year.
Lyra Therapeutics Inc (NASDAQ:LYRA)’s Major holders
CITADEL ADVISORS LLC holds the second largest percentage of outstanding shares, with 7.4562% or 4.77 million shares worth $1.32 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. With 2.52 shares estimated at $0.52 million under it, the former controlled 3.85% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 1.52% of the shares, roughly 992.54 shares worth around $0.21 million.
